What's Going On With G1 Therapeutics Stock?
What's Going On With G1 Therapeutics Stock?
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer.
由于并购博客猜测收购要约，G1 Therapeutics, Inc.（纳斯达克股票代码：GTHX）股价周四走高。
What To Know:
要知道什么：
According to a report from Seeking Alpha, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.
根据Seeking Alpha的一份报告，G1 Therapeutics已收到并拒绝了TerSera Therapeutics的多项报价。根据该报告，有传言称TerSera的一项报价具有或有价值权，该公司的估值可能在每股12至14美元之间。
G1 Therapeutics shares are climbing on heavy trading volume as investors digest the rumors of a possible takeover offer. According to data from Benzinga Pro, more than 25.4 million shares have already been traded in the session, compared to the stock's 100-day average of 1.136 million shares.
随着投资者消化有关可能收购要约的传闻，G1 Therapeutics的股价因大量交易量而攀升。根据Benzinga Pro的数据，该交易日已经交易了超过2540万股股票，而该股的100天平均交易量为113.6万股。
Needham analyst Gil Blum has a Buy rating and $12 price target on G1 Therapeutics, and HC Wainwright & Co. recently maintained its Buy rating and $9 price target on the stock.
Needham分析师吉尔·布鲁姆对G1 Therapeutics的评级为买入，目标股价为12美元，HC Wainwright & Co. 最近维持了该股的买入评级和9美元的目标股价。
Related News: What's Going On With Affirm Stock After Earnings?
相关新闻： 盈利后Affirm股票怎么了？
GTHX Stock Prediction 2024:
2024 年 GTHX 股票预测：
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
股票研究可以成为了解公司基本面的宝贵信息来源。分析师根据公司的基本面和预期的未来收益创建财务模型，以确定股票的目标股价和建议。
Shares of G1 Therapeutics have an average 1-year price target of $10.17, representing an expected upside of 75.65%.
G1 Therapeutics的股票1年平均目标股价为10.17美元，预计上涨幅度为75.65％。
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on G1 Therapeutics, while 6 analysts have bullish ratings. The street high price target from Needham is $12, while the street low from Wedbush is $4.
由于假设的差异，分析师可以得出截然不同的目标价格和建议。没有分析师对G1 Therapeutics提出看跌建议，而6位分析师的评级看涨。尼德姆的街头高价目标价为12美元，而Wedbush的街头最低价为4美元。
GTHX Price Action: According to Benzinga Pro, G1 Therapeutics shares are up 17.85% at $5.06 at the time of publication Thursday.
GTHX价格走势：根据Benzinga Pro的数据，截至周四发布时，G1 Therapeutics的股价上涨了17.85％，至5.06美元。
Image: james-yarema from Unsplash
图片：来自 Unsplash 的 james-yarema